A Bioinformatics Analysis of FAM3A to Identify its Potential Role as a Biomarker in Liver Hepatocellular Cancer

Proceedings of Anticancer Research Pub Date : 2024-08-09 DOI:10.26689/par.v8i4.7461

Syed Hussain Raza

{"title":"A Bioinformatics Analysis of FAM3A to Identify its Potential Role as a Biomarker in Liver Hepatocellular Cancer","authors":"Syed Hussain Raza","doi":"10.26689/par.v8i4.7461","DOIUrl":null,"url":null,"abstract":"Liver hepatocellular cancer (LIHC) is positioned as the third cancer with the highest mortalities worldwide, and high mortalities are associated with late diagnosis and recurrence. This study advances bioinformatics analysis of FAM3A expression in LIHC to evaluate its potential as a prognostic, diagnostic and therapeutic biomarker. Bioinformatics tools such as UALCAN, GEPIA2, KM plotter, TIMER2 and cBioPortal are employed to conduct analysis. Initially, the expression analysis revealed up-regulation of FAM3A in LIHC based on various variables. Further, the study observed that FAM3A methylation regulates expression as variation in methylation level of FAM3A was assessed in LIHC. Moreover, this over-expression of FAM3A results in poor overall survival (OS) in LIHC patients. All of these proposed that FAM3A has a role in the progression and development of LIHC. While examined association of FAM3A expression and infiltration level of CD8+ T cells in LIHC patients using TIMER2 revealed that FAM3A has a positive correlation with purity in LIHC that highlights the molecular landscape. Analysis of genetic alteration revealed minute role of FAM3A in LIHC still provides valuable insight. Overall, our findings reveal that FAM3A has potential as diagnostic, therapeutic and prognostic biomarkers in LIHC.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Anticancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/par.v8i4.7461","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Liver hepatocellular cancer (LIHC) is positioned as the third cancer with the highest mortalities worldwide, and high mortalities are associated with late diagnosis and recurrence. This study advances bioinformatics analysis of FAM3A expression in LIHC to evaluate its potential as a prognostic, diagnostic and therapeutic biomarker. Bioinformatics tools such as UALCAN, GEPIA2, KM plotter, TIMER2 and cBioPortal are employed to conduct analysis. Initially, the expression analysis revealed up-regulation of FAM3A in LIHC based on various variables. Further, the study observed that FAM3A methylation regulates expression as variation in methylation level of FAM3A was assessed in LIHC. Moreover, this over-expression of FAM3A results in poor overall survival (OS) in LIHC patients. All of these proposed that FAM3A has a role in the progression and development of LIHC. While examined association of FAM3A expression and infiltration level of CD8+ T cells in LIHC patients using TIMER2 revealed that FAM3A has a positive correlation with purity in LIHC that highlights the molecular landscape. Analysis of genetic alteration revealed minute role of FAM3A in LIHC still provides valuable insight. Overall, our findings reveal that FAM3A has potential as diagnostic, therapeutic and prognostic biomarkers in LIHC.

查看原文本刊更多论文

对 FAM3A 进行生物信息学分析以确定其作为肝癌生物标志物的潜在作用

肝肝细胞癌（LIHC）是全球死亡率第三高的癌症，高死亡率与晚期诊断和复发有关。本研究对 FAM3A 在 LIHC 中的表达进行了生物信息学分析，以评估其作为预后、诊断和治疗生物标志物的潜力。研究采用了 UALCAN、GEPIA2、KM plotter、TIMER2 和 cBioPortal 等生物信息学工具进行分析。最初，表达分析表明，基于各种变量，FAM3A 在 LIHC 中上调。此外，研究还观察到 FAM3A 甲基化调节了表达，因为在 LIHC 中评估了 FAM3A 甲基化水平的变化。此外，FAM3A的过度表达导致LIHC患者的总生存期（OS）较差。所有这些都表明，FAM3A在LIHC的进展和发展中起着一定的作用。利用TIMER2研究了FAM3A表达与LIHC患者CD8+ T细胞浸润水平的关系，发现FAM3A与LIHC的纯度呈正相关，这凸显了分子图谱。对基因改变的分析揭示了FAM3A在LIHC中的微小作用，这仍然提供了有价值的见解。总之，我们的研究结果表明，FAM3A 具有作为 LIHC 诊断、治疗和预后生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Proceedings of Anticancer Research

自引率

0.00%

发文量